^
BIOMARKER:

STAT5b-RARA fusion

i
Other names: STAT5B, Signal Transducer And Activator Of Transcription 5B, Transcription Factor STAT5B, STAT5, RARA, Retinoic Acid Receptor Alpha, Nuclear Receptor Subfamily 1 Group B Member 1, RAR-Alpha, NR1B1, Nucleophosmin-Retinoic Acid Receptor Alpha Fusion Protein NPM-RAR Long Form, Retinoic Acid Nuclear Receptor Alpha Variant 1, Retinoic Acid Nuclear Receptor Alpha Variant 2, Retinoic Acid Receptor, Alpha Polypeptide, Retinoic Acid Receptor, Alpha, RAR
Entrez ID:
over1year
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review. (PubMed, Medicine (Baltimore))
APL patients with STAT5B-RARa is not only resistant to ATRA, but also to conventional combination chemotherapy such as daunorubicin and cytarabine/idarubicin and cytarabine or other regimens. Relapse and extramedullary infiltration is common, HSCT is a effective treatment, and the best time for HSCT is after the first CR. It should be noted that this patient got CRm with DCAG after relapse, so the role of decitabine in APL with STAT5B-RARa needs to be considered.
Clinical • Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B)
|
STAT5b-RARA fusion
|
cytarabine • decitabine • daunorubicin • idarubicin hydrochloride • arsenic trioxide